Henry Marsh
Overview
Explore the profile of Henry Marsh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aleynick M, Svensson-Arvelund J, Pantsulaia G, Kim K, Rose S, Upadhyay R, et al.
J Immunother Cancer
. 2023 Jul;
11(7).
PMID: 37487664
Background: Cancer immunotherapies are generally effective in patients whose tumors contain a priori primed T-cells reactive to tumor antigens (TA). One approach to prime TA-reactive T-cells is to administer immunostimulatory...
2.
Svensson-Arvelund J, Cuadrado-Castano S, Pantsulaia G, Kim K, Aleynick M, Hammerich L, et al.
Nat Commun
. 2022 Nov;
13(1):7149.
PMID: 36418317
Immunotherapies directly enhancing anti-tumor CD8 T cell responses have yielded measurable but limited success, highlighting the need for alternatives. Anti-tumor T cell responses critically depend on antigen presenting dendritic cells...
3.
Mannas S, Marsh H, Yu Z, Prabhu S, Meenakshi-Sundaram B, Frimberger D, et al.
Urology
. 2021 Apr;
156:e144-e146.
PMID: 33865862
A supernumerary testis is a rare finding with limited description in the literature. Presentations of supernumerary testes vary and often involve initial discovery intraoperatively or in association with a separate...
4.
Hammerich L, Marron T, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S, et al.
Nat Med
. 2019 Apr;
25(5):814-824.
PMID: 30962585
Indolent non-Hodgkin's lymphomas (iNHLs) are incurable with standard therapy and are poorly responsive to checkpoint blockade. Although lymphoma cells are efficiently killed by primed T cells, in vivo priming of...
5.
Hassan M, Ulezko Antonova A, Li J, Hosoba S, Rupji M, Kowalski J, et al.
Biol Blood Marrow Transplant
. 2018 Dec;
25(6):1075-1084.
PMID: 30503387
A higher number of donor plasmacytoid dendritic cells (pDCs) is associated with increased survival and reduced graft-versus-host disease (GVHD) in human recipients of unrelated donor bone marrow (BM) grafts, but...
6.
7.
8.
Thomas L, He L, Marsh H, Keler T
Oncoimmunology
. 2014 Mar;
3(1):e27255.
PMID: 24605266
CD27 is an important co-stimulatory receptor of T cells that can potentially be exploited for immunotherapy. We developed a human IgG1 antibody that targets human CD27, and demonstrated its immunostimulatory...
9.
He L, Prostak N, Thomas L, Vitale L, Weidlick J, Crocker A, et al.
J Immunol
. 2013 Sep;
191(8):4174-83.
PMID: 24026078
The CD70/CD27 pathway plays a significant role in the control of immunity and tolerance, and previous studies demonstrated that targeting murine CD27 (mCD27) with agonist mAbs can mediate antitumor efficacy....
10.
Vitale L, He L, Thomas L, Widger J, Weidlick J, Crocker A, et al.
Clin Cancer Res
. 2012 May;
18(14):3812-21.
PMID: 22589397
Purpose: The TNF receptor superfamily member CD27 is best known for its important role in T-cell immunity but is also recognized as a cell-surface marker on a number of B-...